OnKure Therapeutics
OnKure Therapeutics (Nasdaq: OKUR) is a publicly traded, clinical-stage biopharmaceutical company headquartered in Boulder, Colorado, developing precision medicines for people with cancer. The company designs mutant-selective small-molecule inhibitors against oncogenic drivers in the PI3K pathway; its lead program OKI-219 is a selective PI3K-alpha H1047R inhibitor in clinical development, with additional discovery programs targeting further PI3K-alpha mutations. OnKure became publicly listed through its 2024 combination with Reneo Pharmaceuticals. It is a therapeutics developer rather than a software vendor: it operates a corporate and investor relations web presence and publishes no developer program, public API, SDK, or machine-readable API contract.
OnKure Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Oncology, and Precision Medicine.
OnKure Therapeutics’ developer surface includes support, product news, and 9 more developer resources.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Agent Surfaces 1
MCP servers, agent skills, and machine-readable catalogs
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Commercial 2
Pricing, plans, and the legal terms of use
Company 6
The organization behind the API
Source (apis.yml)
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.